cFluor™ B515 Anti-Human CD141 (M80)
The M80 monoclonal antibody bind to human CD141, a 75-kDa type I membrane glycoprotein. CD141, also known as thrombomodulin, BDCA-3, and fetomodulin, binds to its ligand, thrombin, to form a thrombin-thrombomodulin complex. This complex activates protein C and initiates the Protein C anticoagulant pathway1,2. When bound to CD141, thrombin loses its ability to activate several pro-coagulant proteins3. The molecule is expressed on macrophages, monocytes, dendritic cells, and vascular endothelial cells. The antibody was conjugated to a fluorophore and puriﬁed by afﬁnity chromatography.
Format: cFluor™ B515
Isotype: Mouse IgG1, κ
Tested Dilution: 5 μL / test
Application: Flow Cytometry
Storage: 2-8°C and protected from Light. Do not freeze
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% BSA (Origin USA)
Each lot of this antibody is quality control tested using flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per 1 million cells in a staining volume of 100 µL. If whole blood is analyzed, then use 5 µL per 100 µL. It is recommended that users titrate the antibody to obtain the optimal result for their specific application.
- Sadler JE. Et al. 1997. Thromb Haemost. 78(1):392-5
- Bajzar L, et al. 1996. J Biol Chem. 271(28):16603-8
- Teasdale MS, et al. 1994. Immunol Cell Biol. 72(6):480-8
For Research Use Only. Not intended for use in diagnostic procedures.
*cFluor™ B515 is equivalent to CF®488A manufactured and provided by Biotium, Inc. under an Agreement between Biotium and Cytek (LICENSEE). The manufacture, use, sale, offer for sale, or import of the product is covered by one or more of the patents or pending applications owned or licensed by Biotium. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser’s own internal research. No right under any other patent claim, no right to perform any patented method, and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser's activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel.